SK13892002A3 - Molekula viažuca CD25 na použitie na liečenie zápalových ochorení gastrointestinálneho traktu - Google Patents

Molekula viažuca CD25 na použitie na liečenie zápalových ochorení gastrointestinálneho traktu Download PDF

Info

Publication number
SK13892002A3
SK13892002A3 SK1389-2002A SK13892002A SK13892002A3 SK 13892002 A3 SK13892002 A3 SK 13892002A3 SK 13892002 A SK13892002 A SK 13892002A SK 13892002 A3 SK13892002 A3 SK 13892002A3
Authority
SK
Slovakia
Prior art keywords
tyr
ser
gly
binding molecule
treatment
Prior art date
Application number
SK1389-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Hansjoerg Adam
Lothar F�Rber
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SK13892002A3 publication Critical patent/SK13892002A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK1389-2002A 2000-03-30 2001-03-28 Molekula viažuca CD25 na použitie na liečenie zápalových ochorení gastrointestinálneho traktu SK13892002A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0007911.1A GB0007911D0 (en) 2000-03-30 2000-03-30 Organic compounds
PCT/EP2001/003541 WO2001072845A1 (en) 2000-03-30 2001-03-28 Use of cd25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract

Publications (1)

Publication Number Publication Date
SK13892002A3 true SK13892002A3 (sk) 2003-05-02

Family

ID=9888901

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1389-2002A SK13892002A3 (sk) 2000-03-30 2001-03-28 Molekula viažuca CD25 na použitie na liečenie zápalových ochorení gastrointestinálneho traktu

Country Status (18)

Country Link
US (2) US20050226872A1 (cg-RX-API-DMAC7.html)
EP (1) EP1268553A1 (cg-RX-API-DMAC7.html)
JP (1) JP2003528890A (cg-RX-API-DMAC7.html)
KR (2) KR20020084107A (cg-RX-API-DMAC7.html)
CN (1) CN1416432A (cg-RX-API-DMAC7.html)
AU (2) AU2001246516B2 (cg-RX-API-DMAC7.html)
BR (1) BR0109549A (cg-RX-API-DMAC7.html)
CA (1) CA2401249A1 (cg-RX-API-DMAC7.html)
GB (1) GB0007911D0 (cg-RX-API-DMAC7.html)
HU (1) HUP0301846A3 (cg-RX-API-DMAC7.html)
IL (1) IL151089A0 (cg-RX-API-DMAC7.html)
NO (1) NO20024579L (cg-RX-API-DMAC7.html)
NZ (1) NZ520547A (cg-RX-API-DMAC7.html)
PL (1) PL357014A1 (cg-RX-API-DMAC7.html)
RU (1) RU2286797C2 (cg-RX-API-DMAC7.html)
SK (1) SK13892002A3 (cg-RX-API-DMAC7.html)
WO (1) WO2001072845A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200207736B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081508A2 (en) * 2001-04-06 2002-10-17 University Of Bristol Use of cd25 binding molecules in steroid-resistant patients
WO2009086197A1 (en) * 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
EP2438442B1 (en) 2008-12-01 2017-08-09 Laboratory Corporation of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
US20100233732A1 (en) * 2009-01-15 2010-09-16 Laboratory Corporation Of America Holdings Methods of Determining Patient Response By Measurement of HER-2 Expression
BRPI1007321A2 (en) 2009-01-15 2018-07-10 Laboratory Corporation Of America Holdings methods for measuring and / or quantifying the presence and / or amount of her-3 or her-3 in a complex in a patient sample, and to determine if an individual with cancer is likely to respond to treatment with a targeted therapy. and antibody.
RU2500427C2 (ru) * 2010-07-15 2013-12-10 Олег Ильич Эпштейн Лекарственное средство для лечения функциональных нарушений желудочно-кишечного тракта и способ лечения функциональных нарушений желудочно-кишечного тракта
UY34054A (es) * 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
CA3045944A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
DE69937057T2 (de) * 1998-07-27 2008-05-29 Novartis Ag Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen

Also Published As

Publication number Publication date
RU2286797C2 (ru) 2006-11-10
NO20024579D0 (no) 2002-09-24
IL151089A0 (en) 2003-04-10
PL357014A1 (en) 2004-07-12
AU2001246516B2 (en) 2005-06-30
CA2401249A1 (en) 2001-10-04
NZ520547A (en) 2005-04-29
RU2002127800A (ru) 2004-03-27
WO2001072845A1 (en) 2001-10-04
US20050226872A1 (en) 2005-10-13
HUP0301846A3 (en) 2010-07-28
CN1416432A (zh) 2003-05-07
KR20080079702A (ko) 2008-09-01
ZA200207736B (en) 2003-05-08
EP1268553A1 (en) 2003-01-02
KR20020084107A (ko) 2002-11-04
GB0007911D0 (en) 2000-05-17
JP2003528890A (ja) 2003-09-30
NO20024579L (no) 2002-11-11
US20090041775A1 (en) 2009-02-12
HUP0301846A2 (hu) 2003-09-29
BR0109549A (pt) 2003-06-10
AU4651601A (en) 2001-10-08

Similar Documents

Publication Publication Date Title
US20090041775A1 (en) Use of CD25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract
JP6875363B2 (ja) 神経変性障害の処置のためのセマフォリン−４ｄ結合分子の使用
RU2540018C2 (ru) Средство для лечения заболевания
EP0939652B1 (en) Use of antibodies to cd45ro leukocyte antigen for immunomodulation
JP6694269B2 (ja) Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体
TW200815468A (en) Use of organic compounds
CN104402999A (zh) Trail受体结合剂和其用途
ZA200308999B (en) Anti ngf antibodies for the treatment of various disorders
TW201902514A (zh) Ｐｄ－１抗體與ｖｅｇｆ配體或ｖｅｇｆ受體抑制劑聯合在製備治療腫瘤的藥物中的用途
AU748533B2 (en) Composition and method to prevent graft rejection and other counter-adaptive T lymphocyte mediated immune responses
AU2003303339A1 (en) Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
CN101657215A (zh) 在诊断和治疗类风湿性关节炎中使用的包含抗-cd6单克隆抗体的药物组合物
AU2001246516A1 (en) Use of CD25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract
JP2003528890A5 (cg-RX-API-DMAC7.html)
IL322211A (en) Methods and preparations for combined therapy
DE69630682T2 (de) Synthetische peptide und diese enthaltende arzneimittel zur behandlung des systemischen lupus erythematodes
PT1737490E (pt) Processos de tratamento da aterosclerose
JP3973360B2 (ja) 関節リウマチまたは皮膚疾患の処置に使用するためのｃｄ２５結合分子
CZ20032672A3 (cs) CD25 vazebná molekula pro použití při prevenci nebo léčení některých nemocí u pacientů rezistentních na léčbu steroidy
CN112439060B (zh) Pd-l1免疫疗法的新用途
CN121175335A (zh) Lair-1激动性抗体及其使用方法
EA051900B1 (ru) Антитела против cd112r и варианты их применения
AU2020339737A1 (en) Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells
BRPI0720924A2 (pt) Métodos de tratamento

Legal Events

Date Code Title Description
FC9A Refused patent application